<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Strukturierte Produkte
>
05.07.2019 18:45:00

How Much Revenues Does Roche Stand To Lose Given The FDA Nod For Pfizer's Biosimilar For Avastin?

Roche Holding’s (NASDAQ:RHHBY) oncology portfolio is its largest therapeutic area, and Avastin is one of its top selling drugs. However, it is expected to lose market exclusivity this year, and Pfizer’s Zirabev, a biosimilar to Avastin, was recently approved by the U.S. FDA, while it was already ...
Weiter zum vollständigen Artikel bei "Forbes"

(Anzeige)Passende emittierte Barrier Reverse Convertibles

Basiswert Valor Fälligkeitstag Maximale Rendite p.a.
Companie Financière Richemont SA / LafargeHolcim Ltd. / Roche GS 48927380 16.02.2021 8.42 %